Drugs / Valproate
Valproate
also known as
sodium valproate · Depakote-ER · VPA · Valproate acid · valproic acid · divalproex ER · Divalproex Sodium · magnesium valproate · +8 more
Small molecule targets GSK3B, SMN2 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | DEPAKOTE ER | — | 2003-08-14 – 2009-10-15 | fda.gov ↗ |
| Label expansion | US (FDA) | DEPACON | — | 2002-01-24 | fda.gov ↗ |
| Approved | US (FDA) | DEPACON | — | 1996-12-30 | fda.gov ↗ |
Trials 78 · started per year
today
US approved 1996
1
1
1
1
1
2
7
5
6
5
3
3
1
2
2
5
3
3
2
5
1
4
4
3
1
4
1
19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05017454 | May 2021 → Jan 2023 | alopecia areata | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02144623 | Jan 2015 → Feb 2016 | B-cell chronic lymphocytic leukemia | Lund University Hospital | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06211283 | Sep → Oct 2023 | — | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03681158 | Oct 2018 → Apr 2019 | epilepsy | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02648633 | May 2016 → Feb 2017 | glioblastoma | University of Virginia | Terminated | No outcome recorded |
| Phase 1 | NCT02027987 | Oct 2013 → Dec 2016 | traumatic brain injury | Xijing Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01495104 | Oct 2011 → Jan 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00513162 | Jul 2007 → Sep 2012 | metastatic malignant neoplasm in the brain | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07226141 | Jan 2026 → Sep 2027 expected | ametropic amblyopia, strabismus | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05920512 | Apr 2022 → Apr 2025 | hemophilia | Xue-chun Lu | Unknown | No outcome recorded |
| Phase 1/2 | NCT03825250 | Nov 2018 → Oct 2024 | coronary artery disorder, heart valve disorder, multiple organ dysfunction syndrome | University of Leicester | Unknown | No outcome recorded |
| Phase 1/2 | NCT03616223 | Jul → Dec 2018 | sensorineural hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02899611 | Aug 2016 → Jun 2021 | epilepsy | Cerebral Therapeutics LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01622439 | Jun 2012 → Mar 2018 | diffuse large B-cell lymphoma | Lund University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00240110 | Mar 2006 → Mar 2014 | bipolar disorder, cocaine dependence | University of Miami | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07487675 | Sep 2024 → May 2025 overdue | temporomandibular joint disorder | Tanta University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05694936 | Jan 2023 → Jan 2026 overdue | colorectal cancer | Australasian Gastro-Intestinal Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05224531 | May 2022 → Aug 2024 | pulmonary arterial hypertension | Cereno Scientific AB | Completed | No outcome recorded |
| Phase 2 | NCT04997811 | Dec 2021 → Jan 2025 | myelodysplastic syndrome | Prof. Janet Dunn | Unknown | No outcome recorded |
| Phase 2 | NCT04940572 | Nov 2021 → Nov 2025 | Wolfram syndrome | Centre d'Etude des Cellules Souches | Unknown | No outcome recorded |
| Phase 2 | NCT03717909 | Dec 2018 → Nov 2024 | Wolfram syndrome | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03025906 | Feb 2017 → Oct 2019 | epilepsy with generalized tonic-clonic seizures | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT01730313 | Feb 2016 → Jul 2017 | — | Centers for Disease Control and Prevention | Withdrawn | No outcome recorded |
| Phase 2 | NCT03112889 | Jan 2015 → Apr 2017 | glycogen storage disease V | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01619644 | Apr 2012 → Sep 2014 | Rubinstein-Taybi syndrome | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2 | NCT00634205 | Jul 2006 → Mar 2009 | malignant mesothelioma | European Lung Cancer Working Party | Completed | No outcome recorded |
| Phase 2 | NCT00404508 | Sep 2005 → Oct 2006 | refractory malignant neoplasm | National Institute of Cancerology | Completed | No outcome recorded |
| Phase 2 | NCT00404326 | May 2005 → Nov 2006 | cervical cancer | National Institute of Cancerology | Completed | No outcome recorded |
| Phase 2 | NCT00206778 | Jul 2003 → Jul 2007 | manic bipolar affective disorder | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05431595 | Jul 2022 → Feb 2027 expected | delirium, epilepsy | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02265770 | Jun 2015 → Jun 2028 expected | childhood ependymoma | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00221637 | Mar 2002 → Jul 2005 | neuralgia, neuropathy, painful | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT05603104 | Apr 2025 → Jun 2028 expected | bipolar depression, major depressive disorder, schizophrenia | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT05973786 | Feb 2025 → Jun 2028 expected | bipolar depression | Dr. Inge Winter | Recruiting | No outcome recorded |
| Phase 3 | NCT00533299 | Aug 2007 → Dec 2009 | ovarian cancer | National Institute of Cancerology | Unknown | No outcome recorded |
| Phase 3 | NCT00447369 | May 2007 → Mar 2008 | migraine disorder | Hospital Militar del General Luis Felipe Brieba Aran | Withdrawn | No outcome recorded |
| Phase 3 | NCT00315900 | May 2006 → Dec 2007 | dementia | Tuscaloosa Research & Education Advancement Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT00136110 | Apr 2005 → Feb 2007 | amyotrophic lateral sclerosis | UMC Utrecht | Completed | No outcome recorded |
| Phase 3 | NCT00071721 | Oct 2003 → Feb 2009 | Alzheimer disease | Alzheimer's Disease Cooperative Study (ADCS) | Completed | No outcome recorded |
| Phase 3 | NCT00057681 | Feb 2003 → Dec 2008 | bipolar disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00254774 | Jan 2002 → Mar 2006 | bipolar disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00236717 | Sep 1997 → Nov 2000 | epilepsy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00004817 | Feb 1991 → ? | brain injury, post-traumatic epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT00065884 | — | autism | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06081283 | Nov 2023 → Dec 2024 | brain hypoxia - ischemia, cardiac arrest, intracerebral hemorrhage, traumatic brain injury | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 4 | NCT07046676 | Dec 2022 → Dec 2025 overdue | epilepsy | The First Affiliated Hospital of University of South China | Recruiting | No outcome recorded |
| Phase 4 | NCT03689114 | May 2021 → Jun 2024 | focal epilepsy | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT03652974 | Sep 2018 → Aug 2021 | schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT03235531 | Jul 2017 → Jul 2019 | alcohol abuse, alcohol dependence, alcohol withdrawal | CAMC Health System | Unknown | No outcome recorded |
| Phase 4 | NCT01893229 | Sep 2013 → Dec 2015 | bipolar disorder | Guiyun Xu | Unknown | No outcome recorded |
| Phase 4 | NCT02011750 | Apr 2013 → Oct 2017 | schizophrenia, toxoplasmosis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT01083784 | Mar 2010 → Dec 2012 | cardiac arrest | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00794625 | Nov 2008 → Nov 2012 | attention deficit-hyperactivity disorder | Joseph Blader | Unknown | No outcome recorded |
| Phase 4 | NCT00807989 | Mar 2008 → May 2012 | epilepsy | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00397020 | Dec 2006 → Dec 2008 | bipolar disorder | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00385411 | Mar 2006 → Oct 2008 | epilepsy | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00211250 | Jul 2005 → Jul 2006 | mood disorder | Joliet Center for Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT00139074 | Jul 2005 → Jun 2006 | bipolar disorder | AstraZeneca | Terminated | No outcome recorded |
| Phase 4 | NCT00137709 | Nov 2004 → Jul 2008 | epilepsy | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00194025 | Nov 2004 → Nov 2006 | schizophrenia | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00264173 | Feb 2004 → Sep 2006 | bipolar disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00226343 | Aug 2003 → Jan 2006 | bipolar disorder | Cambridge Health Alliance | Completed | No outcome recorded |
| Phase 4 | NCT00367874 | Feb → Nov 2003 | opiate dependence, substance withdrawal syndrome | Sorlandet Hospital HF | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00153270 | Sep 2000 → Apr 2001 | asthma | Centre of Chinese Medicine, Georgia | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT04218981 | Jan 2020 → Jun 2023 | mental disorder | Central South University | Completed | No outcome recorded |
| — | NCT02556320 | May 2013 → Aug 2015 | drug allergy, epilepsy | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT01791868 | Feb 2013 → Jul 2018 | epilepsy with generalized tonic-clonic seizures | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01463111 | May 2011 → Apr 2016 | bipolar disorder | Emory University | Completed | No outcome recorded |
| — | NCT00570219 | Feb 2005 → May 2008 | substance withdrawal syndrome | University of Helsinki | Completed | No outcome recorded |
| — | NCT00167934 | Dec 2004 → Dec 2008 | schizophrenia | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00159588 | Jan 2004 → Nov 2006 | headache disorder | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT00203242 | Jul 2003 → Sep 2006 | cluster headache syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| — | NCT00222482 | Mar 2003 → Sep 2005 | borderline personality disorder | University of Minnesota | Completed | No outcome recorded |
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 40 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05181007 Comparator | Dec 2021 → Mar 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03903302 Comparator | Oct 2017 → Feb 2018 | thrombotic disease | Cereno Scientific AB | Completed | No outcome recorded |
| Phase 1 | NCT00648076 Comparator | Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02625779 Comparator | Mar 2016 → Apr 2017 | bipolar depression | Ewha Womans University Mokdong Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01543139 Comparator | Dec 2015 → Apr 2017 | bipolar depression | Ewha Womans University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02920060 Comparator | Jan 2015 → Jul 2016 | epilepsy with generalized tonic-clonic seizures | Banaras Hindu University | Completed | No outcome recorded |
| Phase 2 | NCT00000439 Comparator | Oct 2000 → Aug 2003 | alcohol dependence, bipolar disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT06929273 Background | Jul 2025 → Jun 2028 expected | bipolar I disorder | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT05722951 Background | Oct 2022 → Jun 2024 | epilepsy | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04274179 Comparator | Aug 2020 → May 2028 expected | childhood absence epilepsy | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT04698525 Comparator | Feb 2019 → Jan 2020 | migraine disorder | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 3 | NCT01671384 Comparator | Aug 2013 → Dec 2016 | spinal muscular atrophy | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03039842 Comparator | Jan 2013 → Dec 2016 | bipolar II disorder | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01750541 Comparator | Dec 2012 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01342549 Comparator | Sep 2011 → Jun 2015 | alcohol dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT00857584 Background | May 2009 → Feb 2011 | bipolar depression | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00665366 Comparator | Jun 2008 → Oct 2011 | manic bipolar affective disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01188265 Background | Jun 2007 → Dec 2010 | bipolar disorder | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00266630 Background | Nov 2005 → May 2009 | manic bipolar affective disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00175903 Comparator | Feb 2005 → Oct 2007 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00221403 Comparator | Sep 2004 → May 2011 | bipolar I disorder | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT01977300 Background | Jan 2003 → Aug 2011 | bipolar I disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT05881928 Background | Jul 2024 overdue | epilepsy | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04513314 Comparator | Mar 2023 | COVID-19, delirium, viral pneumonia | University of Miami | Withdrawn | No outcome recorded |
| Phase 4 | NCT06089356 Comparator | Jan 2023 → Jan 2024 | migraine disorder | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT05481957 Comparator | Mar 2022 → Jun 2023 | bipolar depression | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT03490487 Background | Jun 2018 → Dec 2020 | self-limited epilepsy with centrotemporal spikes | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03940326 Comparator | Apr 2018 → Oct 2019 | epilepsy with generalized tonic-clonic seizures | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02205931 Comparator | Jan 2015 → Jun 2018 | epilepsy | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT01267864 Comparator | Nov 2010 → Mar 2013 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00713622 Comparator | Jun → Dec 2008 | epilepsy | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00484471 Background | Oct 2007 → Nov 2011 | bipolar disorder | Korea Otsuka International Asia Arab | Completed | No outcome recorded |
| Phase 4 | NCT00375557 Comparator | Oct 2006 → Sep 2007 | Alzheimer disease | University of Cincinnati | Withdrawn | No outcome recorded |
| Phase 4 | NCT00261443 Background | Sep 2005 → Jun 2009 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT03636958 Background | Feb 2021 → Jul 2025 | epilepsy | Assistance Publique Hopitaux De Marseille | Withdrawn | No outcome recorded |
| — | NCT02926976 Comparator | Nov 2016 → Sep 2019 | schizophrenia | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT00774306 Comparator | Apr 2009 → Jun 2012 | subarachnoid hemorrhage | Thomas Jefferson University | Terminated | No outcome recorded |
| — | NCT00742638 Comparator | Mar 2008 → May 2010 | bipolar disorder | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00552500 Comparator | Feb 2003 → Dec 2005 | — | Washington University School of Medicine | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2006-01-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Divalproex Sodium Delayed-Release Tablets tevapharm.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 123 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | valproate | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗69“Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or...” NCT00159588 ↗ “An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).” NCT00857584 ↗ “Part 2 - DDI with valproate (valproic acid [VPA]), a probe substrate for β-oxidation and glucuronidation.” NCT06930872 ↗ “a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)” NCT06549426 ↗ “Valproate (according to response, serum levels, and tolerance) 125-2000mg” NCT01000402 ↗ “carbamazepine, valproate, oxcarbazepine or levetiracetam” NCT03490487 ↗ “Choose lithium or valproate for bipolar disorder group” NCT04218981 ↗ “Ethosuximide, valproate or lamotrigine” NCT04274179 ↗ |
| Known as | DEP | “Sodium Valproate (Depakote, DEP) or placebo (PLA) group” NCT02011750 ↗ |
| Known as | Depacon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203242 ↗ |
| Known as | Depakine | “Depakine (VPA)” NCT04940572 ↗ |
| Known as | Depakine chrono | “treatment by VPA (Depakine chrono)” NCT04940572 ↗ |
| Known as | Depakote | “Depakote (valproate)” NCT00552500 ↗ |
| Known as | Depakote-ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00177567 ↗ |
| Known as | divalproex | “This prospective, 12-week open label study evaluated adjunct extended-release valproate semisodium (divalproex) in 20 older adults with schizophrenia.” PMID 17582828 ↗ Feb 2008 |
| Known as | divalproex ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00397020 ↗ |
| Known as | Divalproex Sodium | “We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate).” PMID 21810649 ↗ Aug 20111“Mylan's divalproex sodium 500 mg extended-release tablets to Abbott's Depakote ER® 500 mg tablets” NCT00648076 ↗ |
| Known as | magnesium valproate | “Patients received hydralazine at 182 mg for rapid, or 83 mg for slow, acetylators, and magnesium valproate at 40 mg/kg, beginning a week before chemotherapy.” PMID 17761710 ↗ Sep 20071“magnesium valproate at an oral dose of 40mg/Kg t.i.d.” NCT00533299 ↗ |
| Known as | sodium valproate | “Anyone of Valproic acid, sodium valproate, or a mixture of the two (sodium valproate) has a mechanism of action characterized by increasing or improving GABA neurotransmission,...” NCT04698525 ↗38“Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy.” PMID 27552848 ↗ Aug 2016 “Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)” NCT02556320 ↗ “ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.” NCT02899611 ↗ “Subjects in group C began to receive sodium valproate sustained-release tablets in combination with the original treatment regimen at week 5.” NCT05481957 ↗ “CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule.” NCT05224531 ↗ “Initially 10-15 mg of sodium valproate/kg bodyweight per day will be taken in one or two doses during meals.” NCT04940572 ↗ “Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate” NCT03616223 ↗ “Sodium valproate tablet 200mg” NCT00742638 ↗ “Sodium Valproate” NCT02205931 ↗ |
| Known as | Valproate acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05973786 ↗ |
| Known as | Valproate Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04698525 ↗ |
| Known as | valproic acid | “For children with cryptogenic generalized epileptic disorders, the AED sodium valproate (valproic acid) has been found to be often effective, has fewer side effects than many...” NCT01730313 ↗2“Valproate (valproic acid), a widely used antiepileptic and mood-stabilizing agent, is also a histone deacetylase (HDAC) inhibitor” NCT07226141 ↗ “Part 2 - DDI with valproate (valproic acid [VPA]), a probe substrate for β-oxidation and glucuronidation.” NCT06930872 ↗ |
| Known as | VPA | “Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen,...” NCT00367874 ↗4“Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.” NCT00774306 ↗ “Sodium valproate (VPA) is a first-line prescription drug widely used in the treatment of epilepsy.” NCT07046676 ↗ “ZYN002 (transdermal), VPA (oral)” NCT06930872 ↗ “Depakine (VPA)” NCT04940572 ↗ |
| Known as | VPA-ER | “extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy.” PMID 27552848 ↗ Aug 2016 |
| Action | Inhibit | “a histone deacetylase inhibitor” PMID 19743466 ↗ Aug 2009 |
| Modality | Small molecule | “Valproate, a short chain fatty acid histone deacetylase inhibitor has been shown to increase the protein level of SMN2” NCT01671384 ↗ |
| Route | Intravenous | “On day 1, the experimental group receives a loading dose of valproate sodium intravenously over 1 hour within 24 hours of injury.” NCT00004817 ↗ |
| Target | SMN2 | “Drugs such as valproic acid, phenylbutyrate, and sodium butyrate that mainly act as histone deacetylase inhibitors can mediate both: they stimulate the SMN2 gene transcription” NCT01671384 ↗ |